Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy
Standard
Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. / Guckenberger, Matthias; Klement, Rainer J; Allgäuer, Michael; Andratschke, Nicolaus; Blanck, Oliver; Boda-Heggemann, Judit; Dieckmann, Karin; Duma, Marciana; Ernst, Iris; Ganswindt, Ute; Hass, Peter; Henkenberens, Christoph; Holy, Richard; Imhoff, Detlef; Kahl, Henning K; Krempien, Robert; Lohaus, Fabian; Nestle, Ursula; Nevinny-Stickel, Meinhard; Petersen, Cordula; Semrau, Sabine; Streblow, Jan; Wendt, Thomas G; Wittig, Andrea; Flentje, Michael; Sterzing, Florian.
in: RADIOTHER ONCOL, Jahrgang 118, Nr. 3, 03.2016, S. 485-91.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy
AU - Guckenberger, Matthias
AU - Klement, Rainer J
AU - Allgäuer, Michael
AU - Andratschke, Nicolaus
AU - Blanck, Oliver
AU - Boda-Heggemann, Judit
AU - Dieckmann, Karin
AU - Duma, Marciana
AU - Ernst, Iris
AU - Ganswindt, Ute
AU - Hass, Peter
AU - Henkenberens, Christoph
AU - Holy, Richard
AU - Imhoff, Detlef
AU - Kahl, Henning K
AU - Krempien, Robert
AU - Lohaus, Fabian
AU - Nestle, Ursula
AU - Nevinny-Stickel, Meinhard
AU - Petersen, Cordula
AU - Semrau, Sabine
AU - Streblow, Jan
AU - Wendt, Thomas G
AU - Wittig, Andrea
AU - Flentje, Michael
AU - Sterzing, Florian
N1 - Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
PY - 2016/3
Y1 - 2016/3
N2 - BACKGROUND AND PURPOSE: To evaluate whether local tumor control probability (TCP) in stereotactic body radiotherapy (SBRT) varies between lung metastases of different primary cancer sites and between primary non-small cell lung cancer (NSCLC) and secondary lung tumors.MATERIALS AND METHODS: A retrospective multi-institutional (n=22) database of 399 patients with stage I NSCLC and 397 patients with 525 lung metastases was analyzed. Irradiation doses were converted to biologically effective doses (BED). Logistic regression was used for local tumor control probability (TCP) modeling and the second-order bias corrected Akaike Information Criterion was used for model comparison.RESULTS: After median follow-up of 19months and 16months (n.s.), local tumor control was observed in 87.7% and 86.7% of the primary and secondary lung tumors (n.s.), respectively. A strong dose-response relationship was observed in the primary NSCLC and metastatic cohort but dose-response relationships were not significantly different: the TCD90 (dose to achieve 90% TCP; BED of maximum planning target volume dose) estimates were 176Gy (151-223) and 160Gy (123-237) (n.s.), respectively. The dose-response relationship was not influenced by the primary cancer site within the metastatic cohort.CONCLUSIONS: Dose-response relationships for local tumor control in SBRT were not different between lung metastases of various primary cancer sites and between primary NSCLC and lung metastases.
AB - BACKGROUND AND PURPOSE: To evaluate whether local tumor control probability (TCP) in stereotactic body radiotherapy (SBRT) varies between lung metastases of different primary cancer sites and between primary non-small cell lung cancer (NSCLC) and secondary lung tumors.MATERIALS AND METHODS: A retrospective multi-institutional (n=22) database of 399 patients with stage I NSCLC and 397 patients with 525 lung metastases was analyzed. Irradiation doses were converted to biologically effective doses (BED). Logistic regression was used for local tumor control probability (TCP) modeling and the second-order bias corrected Akaike Information Criterion was used for model comparison.RESULTS: After median follow-up of 19months and 16months (n.s.), local tumor control was observed in 87.7% and 86.7% of the primary and secondary lung tumors (n.s.), respectively. A strong dose-response relationship was observed in the primary NSCLC and metastatic cohort but dose-response relationships were not significantly different: the TCD90 (dose to achieve 90% TCP; BED of maximum planning target volume dose) estimates were 176Gy (151-223) and 160Gy (123-237) (n.s.), respectively. The dose-response relationship was not influenced by the primary cancer site within the metastatic cohort.CONCLUSIONS: Dose-response relationships for local tumor control in SBRT were not different between lung metastases of various primary cancer sites and between primary NSCLC and lung metastases.
U2 - 10.1016/j.radonc.2015.09.008
DO - 10.1016/j.radonc.2015.09.008
M3 - SCORING: Journal article
C2 - 26385265
VL - 118
SP - 485
EP - 491
JO - RADIOTHER ONCOL
JF - RADIOTHER ONCOL
SN - 0167-8140
IS - 3
ER -